Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821553 | 0.82 | TAAR1 (0.46) | TAAR1NR3C1ACHETSHRCHRM2 | |
| SCHEMBL24848861 | 0.81 | TAAR1 (0.42) | TAAR1NR3C1ACHETSHRCHRM2 | |
| SCHEMBL25681350 | 0.80 | TAAR1 (0.45) | TAAR1NR3C1ACHETSHRCHRM2 | |
| SCHEMBL28443237 | 0.77 | TAAR1 (0.46) | TAAR1ACHETSHRCHRM2PTGS1 | |
| SCHEMBL3167835 | 0.75 | RIPK1 (0.48) | TAAR1NR3C1ACHETSHRCHRM2 | |
| SCHEMBL18262834 | 0.74 | HSPA5 (0.50) | TAAR1TSHRKDM4EKMT2A | |
| SCHEMBL808983 | 0.71 | TAAR1 (0.45) | TAAR1NR3C1ACHETSHRCHRM2 | |
| SCHEMBL15976426 | 0.71 | TAAR1 (0.45) | TAAR1NR3C1ACHETSHRCHRM2 | |
| SCHEMBL3638610 | 0.71 | TAAR1 (0.52) | TAAR1ACHETSHRCHRM2PTGS1 | |
| SCHEMBL13722854 | 0.71 | TAAR1 (0.45) | TAAR1NR3C1ACHETSHRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435446-B1 | FLUORINATED SILYLETHYNYL PENTACENE COMPOUNDS AND COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8920679-B2 | Fluorinated silylethynyl pentacene compounds and compositions and methods of making and using the same | 3M INNOVATIVE PROPERTIES CO. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20120061620-A1 | Fluorinated Silyethynyl Pentacene Compounds and Compositions and Methods of Making and Using the Same | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-15 | — | — | US | disclosed |
| WO-2010138807-A1 | FLUORINATED SILYLETHYNYL PENTACENE COMPOUNDS AND COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120061620-A1 | Fluorinated Silyethynyl Pentacene Compounds and Compositions and Methods of Making and Using the Same | PFAS, FLNB, FLNA | TAAR1 3353/4885NR3C1 3774/4885ACHE 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.